Latest News
-
Bagsværd, Denmark – Novo Nordisk today confirms that it made a proposal on 22 December 2017 to acquire Ablynx for €28.00 per share in cash and one CVR with total potential cash payments over time of up to €2.50 per share. This proposal implies a total equity valuation of approximately €2.6 billion1 for... -
PARIS, France and CAMBRIDGE, MA, USA – Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically: Sanofi will obtain global development and commercialization rights...
-
VANCOUVER, British Columbia – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, provided key accomplishments from the past year and announced priorities for 2018. “2017 was a great year for Zymeworks and we are poised to achieve a number of important corporate milestones in 2018,” said Ali Tehrani,...
Videos
Rare disease spotlight
Have you already checked #CheckOrphan? Learn about #RareDiseases, their #symptoms and #treatments at http://5.102.147.165/diseases
Learn more about #RareDiseases and #OrphanDrugs on #CheckOrphan. Join our #FreeNewsletter at http://5.102.147.165/news
Have you already checked #CheckOrphan? Learn about #RareDiseases, their #symptoms and #treatments at http://5.102.147.165/diseases